Phase II Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Patients with Carcinoid Syndrome
The purpose of this trial is to evaluate the safety and tolerability of paltusotine in patients with pancreatic neuroendocrine tumors with symptomatic carcinoid syndrome.
Study ID: CRN00808-11
Trial Phase: Phase II
Trial Sponsor: Crinetics Pharmaceuticals Inc.
Therapies Used in This Trial: